Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues

Sung Kwan Hwang, A. Juhász, Sung Hwa Yoon, Nicholas Bodor

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In the search for more potent but still short-acting β-blockers (BB), the methyl, ethyl, isopropyl, tert-butyl, cyclohexyl, 2-(1-adamantyl)ethyl, and methylthiomethyl esters of the acidic inactive metabolite of bufuralol were synthesized based on the 'inactive metabolite' approach. The cleavage of the ester bond by blood and tissue esterases rapidly deactivates these compounds, resulting in an ultrashort duration of action. The β-antagonist potencies and time courses of actions of the new 'soft' BBs were characterized by recording ECG and intra-arterial blood pressure (BP) in rats. In the isoproterenol-induced tachycardia model, while bufuralol at an iv dose of 1 mg/kg (3.8 μmol/kg) diminished heart rate (HR) for at least 2 h, the effects of the soft drugs lasted for only 10-30 min at equimolar dose. The inactive metabolite did not decrease HR significantly. The first four members of this series of compounds showed the highest β-blocking potencies, ranging between 25% and 50‰ of that of bufuralol. Next, the effects of these most active compounds on resting HR and BP were evaluated in comparison to esmolol. Infused for 10 min at a rate of 20 μmol/kg/min, esmolol decreased HR and mean arterial pressure (MAP) by 40‰ and 60‰, respectively. The soft drugs at doses ranging only between 2 and 4 μmol/kg/min resulted in a 20- 40‰ decrease in HR and a 30-50‰ reduction in MAP. However, the time courses of both the bradycardic and hypotensive effects of the soft drugs were superimposable to that of esmolol, diminishing within 60 min after the discontinuation of the infusions.

Original languageEnglish
Pages (from-to)1525-1532
Number of pages8
JournalJournal of Medicinal Chemistry
Volume43
Issue number8
DOIs
Publication statusPublished - Aug 20 2000

Fingerprint

Heart Rate
Metabolites
Arterial Pressure
Pharmaceutical Preparations
Blood pressure
Esters
Esterases
Electrocardiography
Isoproterenol
Tachycardia
Rats
Blood
bufuralol
Tissue
Blood Pressure
esmolol

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues. / Hwang, Sung Kwan; Juhász, A.; Yoon, Sung Hwa; Bodor, Nicholas.

In: Journal of Medicinal Chemistry, Vol. 43, No. 8, 20.08.2000, p. 1525-1532.

Research output: Contribution to journalArticle

Hwang, Sung Kwan ; Juhász, A. ; Yoon, Sung Hwa ; Bodor, Nicholas. / Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues. In: Journal of Medicinal Chemistry. 2000 ; Vol. 43, No. 8. pp. 1525-1532.
@article{492ef37cc4784c1d889ebadef44d68f8,
title = "Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues",
abstract = "In the search for more potent but still short-acting β-blockers (BB), the methyl, ethyl, isopropyl, tert-butyl, cyclohexyl, 2-(1-adamantyl)ethyl, and methylthiomethyl esters of the acidic inactive metabolite of bufuralol were synthesized based on the 'inactive metabolite' approach. The cleavage of the ester bond by blood and tissue esterases rapidly deactivates these compounds, resulting in an ultrashort duration of action. The β-antagonist potencies and time courses of actions of the new 'soft' BBs were characterized by recording ECG and intra-arterial blood pressure (BP) in rats. In the isoproterenol-induced tachycardia model, while bufuralol at an iv dose of 1 mg/kg (3.8 μmol/kg) diminished heart rate (HR) for at least 2 h, the effects of the soft drugs lasted for only 10-30 min at equimolar dose. The inactive metabolite did not decrease HR significantly. The first four members of this series of compounds showed the highest β-blocking potencies, ranging between 25{\%} and 50‰ of that of bufuralol. Next, the effects of these most active compounds on resting HR and BP were evaluated in comparison to esmolol. Infused for 10 min at a rate of 20 μmol/kg/min, esmolol decreased HR and mean arterial pressure (MAP) by 40‰ and 60‰, respectively. The soft drugs at doses ranging only between 2 and 4 μmol/kg/min resulted in a 20- 40‰ decrease in HR and a 30-50‰ reduction in MAP. However, the time courses of both the bradycardic and hypotensive effects of the soft drugs were superimposable to that of esmolol, diminishing within 60 min after the discontinuation of the infusions.",
author = "Hwang, {Sung Kwan} and A. Juh{\'a}sz and Yoon, {Sung Hwa} and Nicholas Bodor",
year = "2000",
month = "8",
day = "20",
doi = "10.1021/jm9904654",
language = "English",
volume = "43",
pages = "1525--1532",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues

AU - Hwang, Sung Kwan

AU - Juhász, A.

AU - Yoon, Sung Hwa

AU - Bodor, Nicholas

PY - 2000/8/20

Y1 - 2000/8/20

N2 - In the search for more potent but still short-acting β-blockers (BB), the methyl, ethyl, isopropyl, tert-butyl, cyclohexyl, 2-(1-adamantyl)ethyl, and methylthiomethyl esters of the acidic inactive metabolite of bufuralol were synthesized based on the 'inactive metabolite' approach. The cleavage of the ester bond by blood and tissue esterases rapidly deactivates these compounds, resulting in an ultrashort duration of action. The β-antagonist potencies and time courses of actions of the new 'soft' BBs were characterized by recording ECG and intra-arterial blood pressure (BP) in rats. In the isoproterenol-induced tachycardia model, while bufuralol at an iv dose of 1 mg/kg (3.8 μmol/kg) diminished heart rate (HR) for at least 2 h, the effects of the soft drugs lasted for only 10-30 min at equimolar dose. The inactive metabolite did not decrease HR significantly. The first four members of this series of compounds showed the highest β-blocking potencies, ranging between 25% and 50‰ of that of bufuralol. Next, the effects of these most active compounds on resting HR and BP were evaluated in comparison to esmolol. Infused for 10 min at a rate of 20 μmol/kg/min, esmolol decreased HR and mean arterial pressure (MAP) by 40‰ and 60‰, respectively. The soft drugs at doses ranging only between 2 and 4 μmol/kg/min resulted in a 20- 40‰ decrease in HR and a 30-50‰ reduction in MAP. However, the time courses of both the bradycardic and hypotensive effects of the soft drugs were superimposable to that of esmolol, diminishing within 60 min after the discontinuation of the infusions.

AB - In the search for more potent but still short-acting β-blockers (BB), the methyl, ethyl, isopropyl, tert-butyl, cyclohexyl, 2-(1-adamantyl)ethyl, and methylthiomethyl esters of the acidic inactive metabolite of bufuralol were synthesized based on the 'inactive metabolite' approach. The cleavage of the ester bond by blood and tissue esterases rapidly deactivates these compounds, resulting in an ultrashort duration of action. The β-antagonist potencies and time courses of actions of the new 'soft' BBs were characterized by recording ECG and intra-arterial blood pressure (BP) in rats. In the isoproterenol-induced tachycardia model, while bufuralol at an iv dose of 1 mg/kg (3.8 μmol/kg) diminished heart rate (HR) for at least 2 h, the effects of the soft drugs lasted for only 10-30 min at equimolar dose. The inactive metabolite did not decrease HR significantly. The first four members of this series of compounds showed the highest β-blocking potencies, ranging between 25% and 50‰ of that of bufuralol. Next, the effects of these most active compounds on resting HR and BP were evaluated in comparison to esmolol. Infused for 10 min at a rate of 20 μmol/kg/min, esmolol decreased HR and mean arterial pressure (MAP) by 40‰ and 60‰, respectively. The soft drugs at doses ranging only between 2 and 4 μmol/kg/min resulted in a 20- 40‰ decrease in HR and a 30-50‰ reduction in MAP. However, the time courses of both the bradycardic and hypotensive effects of the soft drugs were superimposable to that of esmolol, diminishing within 60 min after the discontinuation of the infusions.

UR - http://www.scopus.com/inward/record.url?scp=0034692180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034692180&partnerID=8YFLogxK

U2 - 10.1021/jm9904654

DO - 10.1021/jm9904654

M3 - Article

VL - 43

SP - 1525

EP - 1532

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 8

ER -